Moleculin Biotech 8-K cites Oct 5, 2026 investor presentation; exhibit content not included

Moleculin Biotech, Inc.

Moleculin Biotech (MBRX) said it is using an attached corporate presentation posted on its website, dated October 5, 2026, per the filing signed by Jonathan P. Foster.
Exhibit 99.1 contains no presentation text, slides, data tables, or figures - only the exhibit title - so no clinical, pipeline, or financial updates are available in this filing.
No earnings, guidance, trial results, financing terms, or partnership details appear anywhere in the filing body or the appended exhibit.
Investors seeking the actual corporate presentation content must retrieve it directly from the company's website; it cannot be summarized from this document.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.